BIO and Campbell Alliance Release Two New Industry Reports on Deal-Making Trends at the 2010 BIO International Convention
WASHINGTON, D.C. (Wednesday, May 05, 2010) -
Contact: Tracy Krughoff
BIO and Campbell Alliance Release Two New Industry Reports on
Deal-Making Trends at the 2010 BIO International Convention
WASHINGTON, D.C. (May 5, 2010) ? The Biotechnology Industry Organization (BIO) and the Campbell Alliance today released the 2010 Dealmakers' Intentions Survey and the BIO Business Forum Partnering Report at the 2010 BIO International Convention, May 3-6 in Chicago, Ill., at McCormick Place.
BIO and the Campbell Alliance shared key findings from two unique forward-looking measures of deal-making in the biotech industry. Panelists explored the assets and target market segments that are in demand as well as the partnering and drug development strategies of both large and emerging companies.
"We're pleased to offer these two timely reports on deal-making trends to our attendees," said Jim Greenwood, President and CEO of BIO. "In this uncertain economic climate, the partnerships and collaborations between the biotechnology and pharmaceutical industries are critical to the future of both industries."
Panelists for this Super Session included:
- Ben Bonifant - Chair, Vice President and Head, Business Development Practice, Campbell Alliance
- John Craighead, PhD, Chair, Managing Director, Investor Relations and Business Development, BIO
- BJ Bormann, PhD, Senior Vice President & Global Head, Business Development, Boehringer Ingelheim
- Shaun Grady, Vice President, Strategic Partnering & Business Development, AstraZeneca
- James Sabry, MD, PhD, Vice President, Genentech Partnering, Genentech
- Paul J. Hastings, President and Chief Executive Officer, OncoMed Pharmaceuticals
Highlights from the BIO Business Forum Partnering Report:
- One-on-one partnering meetings can be used to assess forward looking dealmaker intentions.
- Phase II assets are in high demand.
- Oncology and CNS have high-supply and high interest.
- Cardiovascular, respiratory and immunology have high interest and lower supply.
"Deal-making is and will continue to be a fundamental part of the biotechnology and pharmaceutical industries," said John Craighead, PhD, Chair, Managing Director, Investor Relations and Business Development, BIO. "These reports represent a unique forward-looking view of business development trends and are remarkably consistent with one another."
Highlights from the Campbell Alliance 2010 Dealmakers' Intentions Survey:
- Respondents with commercial operations expect levels of Phase III deal-making to remain steady.
- Survey respondents were optimistic about Phase II deal-making activity.
- There is strong interest for Phase II programs, particularly among in-licensors.
- Deal-making is concentrated in oncology, CNS and pain.
- There are few products available in areas such as cardiovascular and metabolic.
"For out-licensors, if you're operating in a competitive therapeutic area, it's critical that you align your development and your partnering program to highlight the factors that are influencing in-licensors' priorities in your category," stated Ben Bonifant, Vice President and Head, Business Development Practice, Campbell Alliance.
The 2010 BIO International Convention also hosts the BIO Business Forum, the world's largest life sciences partnering event. With 150 company presentations in more than 35 therapeutic categories and more than 15,000 one-on-one meetings, the BIO Business Forum plays a critical role in the development of collaborations to advance innovations that help heal, fuel and feed the world.
The annual BIO International Convention helps to support the association's programs and initiatives. BIO works throughout the year to create a policy environment that enables the industry to continue to fulfill its vision of bettering the world through biotechnology innovation.
For more information and a full Convention program, please visit https://mail.bio.org/owa/redir.aspx?C=9befde954658457088aacd2471380c27&URL=http%3a%2f%2fconvention.bio.org%2f.
BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.